Investigational drug · Phase 3
ARDT
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "ARDT"
First trial start
2021
Jun 9, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARDT", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ARDT" as an intervention, largest first.
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04720157 · 1,144 participants · Start Jun 9, 2021 · Primary completion Jan 13, 2025
Drug: 177Lu-PSMA-617; 68Ga-PSMA-11 and 2 more · For: Prostatic Neoplasms
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 164 sites in all
- Metastasis-directed Therapy for Oligorecurrent Prostate CancerPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT05352178 · 873 participants (planned) · Start Apr 20, 2022 · Primary completion Apr 25, 2027
Drug: Androgen deprivation therapy; Androgen receptor targeted therapy · For: Prostate Cancer; Prostate Cancer Recurrent; Prostate Cancer Metastatic and 4 more
Sites: Leuven, Belgium
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Pivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06691984 · 707 participants · Start Dec 9, 2024 · Primary completion Jan 2, 2029
Drug: Xaluritamig; Abiraterone and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Birmingham, Alabama; Duarte, California; Fullerton, California · 164 sites in all
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04689828 · 469 participants · Start Jun 15, 2021 · Primary completion Oct 2, 2022
Drug: 177Lu-PSMA-617; 68Ga-PSMA-11 and 1 more · For: Prostatic Neoplasms
Sites: Denver, Colorado; Gainesville, Florida; New Orleans, Louisiana · 72 sites in all
Nurix Therapeutics, Inc.Industry
NCT05107674 · 345 participants (planned) · Start Sep 29, 2021 · Primary completion Aug 31, 2026
Drug: NX-1607; Paclitaxel · For: Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer and 11 more
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 17 sites in all
- Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or EnzalutamidePivotal-lookingCompleted
Alliance Foundation Trials, LLC.Academic, hospital or other
NCT04335682 · 111 participants · Start Aug 17, 2021 · Primary completion Sep 1, 2025
Drug: Darolutamide; Enzalutamide · For: Metastatic Prostate Cancer; Prostate Cancer Metastatic; Prostate Cancer and 3 more
Sites: San Francisco, California; Chicago, Illinois; Fairway, Kansas · 8 sites in all
GlaxoSmithKlineGSK (GSK)
NCT03150056 · 73 participants · Start Jul 18, 2017 · Primary completion Jul 31, 2020
Drug: GSK525762; Abiraterone and 2 more · For: Solid Tumours
Sites: Los Angeles, California; Baltimore, Maryland; Towson, Maryland · 20 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05658003 · 63 participants · Start May 5, 2023 · Primary completion Dec 2, 2024
Drug: [177Lu]Lu-PSMA-617; ARDT and 1 more · For: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sites: Wuhan, China; Nanjing, China; Shenyang, China · 15 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02924766 · 34 participants · Start Oct 3, 2016 · Primary completion Jul 18, 2019
Drug: Niraparib; Apalutamide and 2 more · For: Prostatic Neoplasms
Sites: West Hollywood, California; Louisville, Kentucky; Portland, Oregon · 6 sites in all
- Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLTActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05983198 · 33 participants · Start Nov 7, 2023 · Primary completion Mar 4, 2031
Drug: 225Ac-PSMA-R2 · For: Prostate Cancer
Sites: Rochester, Minnesota; Darlinghurst, Australia; Montreal, Canada · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Paper spray mass spectrometry for rapid toxicology targeted screening of emergency department samples: a research study.
Boccuzzi S, Cowan D, Dargan PI, et al. · J Anal Toxicol 2026
- Interpretive Reference Ranges for Plasma Drug Concentrations in Acute Recreational Drug Toxicity: A Short Communication.
Boccuzzi S, Battal D, Cowan D, et al. · Ther Drug Monit 2026
- Olfactory dysfunction with traumatic brain injury and posttraumatic-stress symptoms in post-deployed military personnel.
Shura RD, Pickett TC, Powell J, et al. · Front Neurol 2025
- Personality assessment inventory sex differences in people with epileptic and functional seizures.
Smith MP, Kordovski VM, Del Bene VA, et al. · Epilepsy Behav 2025
- Comparison of Laboratory Confirmed Drugs in Acute Recreational Drug Toxicity Presentations to an Urban Hospital in London, UK, 2016/17 versus 2019/20.
Wolfe CE, Sund LJ, Archer JR, et al. · J Med Toxicol 2025
- Association Between Betrayal Trauma and the PAI Traumatic Stress Scale.
Hujing CL, Yalch MM, Levendosky AA · J Trauma Dissociation 2024
Also in development for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- PasritamigJNJ-78278343Phase 34 trials
Johnson & Johnson (Janssen) · Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- FuzuloparibPhase 31 trial
Jiangsu HengRui Medicine Co., Ltd. · Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- REGN5678NezastomigPhase 23 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- GI-102Phase 22 trials
GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
- REGN4336Phase 22 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- vudalimabPhase 22 trials
Xencor, Inc. · Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.